

Clinical Note

Patient Name: John Smith
Date of Birth: 1965-03-15
Date of Note: November 18, 2025

Diagnosis & Disease Status

Primary Diagnosis: Lung cancer
ICD-10 Code: C34.90
Disease Stage: Stage IIIB (Note: Assumed based on platinum chemotherapy prior)
Performance Status: ECOG 1 (Note: Assumed for active treatment)

Clinical History

- Prior Therapies:**
- Platinum chemotherapy
- Current Line of Therapy:**
- Second-line (post-platinum chemotherapy)
- Medication History:**
- Platinum chemotherapy

Biomarker & Laboratory Results

Biomarker / Test	Result	Comments
PD-L1	65%	Predicts pembrolizumab response
EGFR / ALK	Negative	No targetable mutation

Assessment & Plan

- Assessment:**
Patient with Stage IIIB lung cancer, status post-platinum chemotherapy. Biomarker analysis reveals PD-L1 expression of 65% and negative EGFR/ALK status, supporting the use of immunotherapy.
- Treatment Plan:**
- Planned Treatment:** Pembrolizumab

Insurance Information

Provider: UnitedHealth

Policy ID: INS12345

Coverage Period: 2025-01-01 to 2025-12-31

Eligibility Status: ACTIVE